secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2025-07-10T23:59:59+00:00
Accession:  0001641172-25-018600
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal to present Phase 1 data for norovirus inhibitor CDI-988 at Calicivirus Conference
--------------------------------------------------------------------------------

- CDI-988 is a first-in-class pan-viral protease inhibitor targeting norovirus and coronaviruses.
- Oral presentation by co-CEO Sam Lee on Sept 11, 2025 at the 9th International Calicivirus Conference in Banff.
- Phase 1 study completed evaluating safety, tolerability, pharmacokinetics, and food effect in healthy adults.
- No approved vaccine or antiviral exists for norovirus; CDI-988 targets a conserved region of 3CL protease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000164117225018600/0001641172-25-018600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000164117225018600/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-018600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer